Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Pfizer pledges $100M to new Antimicrobial Resistance Action Fund » 15:23
07/09/20
07/09
15:23
07/09/20
15:23
PFE

Pfizer

$33.57 /

-0.19 (-0.56%)

, AMGN

Amgen

$252.34 /

+0.74 (+0.29%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, LLY

Eli Lilly

$166.59 /

-2.52 (-1.49%)

, GSK

GlaxoSmithKline

$40.37 /

-0.35 (-0.86%)

, MRK

Merck

$76.99 /

-0.88 (-1.13%)

, MKGAY

Merck KGaA

$0.00 /

+ (+0.00%)

, TEVA

Teva

$11.60 /

+0.21 (+1.84%)

, TAK

Takeda Pharmaceutical

$17.36 /

-0.135 (-0.77%)

, NVO

Novo Nordisk

$65.63 /

-0.23 (-0.35%)

, JNJ

Johnson & Johnson

$143.03 /

-0.21 (-0.15%)

, NVS

Novartis

$87.53 /

-0.585 (-0.66%)

Pfizer (PFE) announced…

Pfizer (PFE) announced earlier it has pledged $100M to the new Antimicrobial Resistance, or "AMR," Action Fund, which launched today, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections. "The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies that aims to bring 2-4 new antibiotics to patients by 2030 through collaboration between pharmaceutical companies, philanthropies, development banks, and multilateral organizations to re-invigorate and accelerate antibiotic development," the company stated. "As the COVID-19 pandemic has shown, we must invest in the development of medicines now so that we are prepared to help prevent the next public health crisis," added Pfizer Chairman and CEO Albert Bourla. Other investors in the AMR Action Fund include Amgen (AMGN), Bayer (BAYRY), Roche (RHHBY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Merck (MRK), Merck KGaA (MKGAY), Teva (TEVA), Takeda Pharmaceutical (TAK), Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Novartis (NVS). Reference Link

ShowHide Related Items >><<
TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
AMGN Amgen
$252.34 /

+0.74 (+0.29%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

07/09/20 Morgan Stanley
Eli Lilly won't publish Phase 1 COVID antibody data, says Morgan Stanley
06/29/20 Mizuho
Eli Lilly price target raised to $164 from $155 at Mizuho
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
MRK Merck
$76.99 /

-0.88 (-1.13%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

05/15/20 Nord/LB
Merck KGaA downgraded to Hold from Buy at Nord/LB
03/06/20 UBS
UBS backs Neutral on Merck KGaA after Q4 results
12/02/19 Goldman Sachs
Merck KGaA reinstated with a Sell at Goldman Sachs
10/04/19 Loop Capital
Entegris price target raised to $51 from $47 at Loop Capital
TEVA Teva
$11.60 /

+0.21 (+1.84%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$87.53 /

-0.585 (-0.66%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

Hot Stocks
Mylan announces FDA approval for Hulio » 06:37
07/09/20
07/09
06:37
07/09/20
06:37
MYL

Mylan

$16.20 /

+0.09 (+0.56%)

, ABBV

AbbVie

$99.28 /

-0.06 (-0.06%)

Mylan (MYL) and Fujifilm…

Mylan (MYL) and Fujifilm Kyowa Kirin announced that the FDA has approved Hulio, a biosimilar to AbbVie's (ABBV) Humira, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis, in both prefilled syringe and auto-injector presentations. In accordance with its patent license agreement with AbbVie, Mylan will be able to launch Hulio in the U.S. during July 2023.

ShowHide Related Items >><<
MYL Mylan
$16.20 /

+0.09 (+0.56%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

MYL Mylan
$16.20 /

+0.09 (+0.56%)

06/18/20 Raymond James
Raymond James says Mylan win over Biogen has 'no real apparent financial upside'
06/18/20 Wedbush
Patent ruling 'creates a significant issue' for Biogen, says Wedbush
03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

07/07/20 SunTrust
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
MYL Mylan
$16.20 /

+0.09 (+0.56%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

MYL Mylan
$16.20 /

+0.09 (+0.56%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

MYL Mylan
$16.20 /

+0.09 (+0.56%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

MYL Mylan
$16.20 /

+0.09 (+0.56%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

Conference/Events
Oxford Global Marketing to hold a virtual event » 04:55
07/09/20
07/09
04:55
07/09/20
04:55
ABBV

AbbVie

$99.28 /

-0.06 (-0.06%)

, AZN

AstraZeneca

$54.19 /

+0.7 (+1.31%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$59.58 /

-0.72 (-1.19%)

, GSK

GlaxoSmithKline

$40.72 /

+0.34 (+0.84%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

, JAZZ

Jazz Pharmaceuticals

$107.54 /

-1.18 (-1.09%)

, JNJ

Johnson & Johnson

$143.24 /

+0.43 (+0.30%)

, NVS

Novartis

$88.12 /

+0.345 (+0.39%)

, PFE

Pfizer

$33.76 /

-0.27 (-0.79%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RTRX

Retrophin

$20.86 /

-0.04 (-0.19%)

, SNY

Sanofi

$51.54 /

+0.14 (+0.27%)

, TAK

Takeda Pharmaceutical

$17.49 /

+0.01 (+0.06%)

, TEVA

Teva

$11.39 /

+0.17 (+1.52%)

Formulation &…

Formulation & Delivery Series Biomanufacturing Virtual Congress will be held on July 8-9. Webcast Link

ShowHide Related Items >><<
TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

07/07/20 SunTrust
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
IPSEY Ipsen
$0.00 /

+ (+0.00%)

06/08/20 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
06/01/20 Barclays
Ipsen price target raised to EUR 72 from EUR 62 at Barclays
06/01/20 BofA
Ipsen upgraded to Buy from Neutral at BofA
05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

06/23/20 Barclays
Jazz Pharmaceuticals price target raised to $195 from $183 at Barclays
06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$88.12 /

+0.345 (+0.39%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.76 /

-0.27 (-0.79%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
08/23/19 BMO Capital
Retrophin price target lowered to $33 from $38 at BMO Capital
SNY Sanofi
$51.54 /

+0.14 (+0.27%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TEVA Teva
$11.39 /

+0.17 (+1.52%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TEVA Teva
$11.39 /

+0.17 (+1.52%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

  • 09
    Jun
TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

TEVA Teva
$11.39 /

+0.17 (+1.52%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

Wednesday
Conference/Events
Oxford Global Marketing to hold a virtual event » 09:24
07/08/20
07/08
09:24
07/08/20
09:24
ABBV

AbbVie

$99.34 /

+0.31 (+0.31%)

, AZN

AstraZeneca

$53.49 /

-0.61 (-1.13%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$60.30 /

+0.09 (+0.15%)

, GSK

GlaxoSmithKline

$40.38 /

-0.625 (-1.52%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

, JAZZ

Jazz Pharmaceuticals

$108.72 /

-2.48 (-2.23%)

, JNJ

Johnson & Johnson

$142.81 /

-0.18 (-0.13%)

, NVS

Novartis

$87.77 /

-0.65 (-0.74%)

, PFE

Pfizer

$34.03 /

-0.48 (-1.39%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RTRX

Retrophin

$20.90 /

+0.34 (+1.65%)

, SNY

Sanofi

$51.40 /

-0.78 (-1.49%)

, TAK

Takeda Pharmaceutical

$17.48 /

-0.18 (-1.02%)

, TEVA

Teva

$11.22 /

-0.31 (-2.69%)

Formulation &…

Formulation & Delivery Series Biomanufacturing Virtual Congress will be held on July 8-9. Webcast Link

ShowHide Related Items >><<
TEVA Teva
$11.22 /

-0.31 (-2.69%)

TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RTRX Retrophin
$20.90 /

+0.34 (+1.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

07/07/20 SunTrust
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
IPSEY Ipsen
$0.00 /

+ (+0.00%)

06/08/20 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
06/01/20 Barclays
Ipsen price target raised to EUR 72 from EUR 62 at Barclays
06/01/20 BofA
Ipsen upgraded to Buy from Neutral at BofA
05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

06/23/20 Barclays
Jazz Pharmaceuticals price target raised to $195 from $183 at Barclays
06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$87.77 /

-0.65 (-0.74%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$34.03 /

-0.48 (-1.39%)

07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
RTRX Retrophin
$20.90 /

+0.34 (+1.65%)

06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
08/23/19 BMO Capital
Retrophin price target lowered to $33 from $38 at BMO Capital
SNY Sanofi
$51.40 /

-0.78 (-1.49%)

07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
06/24/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TEVA Teva
$11.22 /

-0.31 (-2.69%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TEVA Teva
$11.22 /

-0.31 (-2.69%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RTRX Retrophin
$20.90 /

+0.34 (+1.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

  • 09
    Jun
TEVA Teva
$11.22 /

-0.31 (-2.69%)

TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

TEVA Teva
$11.22 /

-0.31 (-2.69%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

TEVA Teva
$11.22 /

-0.31 (-2.69%)

TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

Hot Stocks
Berkshire Hathaway's Buffet contributes $2.9B to five philanthropies » 06:33
07/08/20
07/08
06:33
07/08/20
06:33
BRK.A

Berkshire Hathaway

$271,420.00 /

-3210.57 (-1.17%)

, BRK.B

Berkshire Hathaway

$181.10 /

-1.68 (-0.92%)

Yesterday, Warren…

Yesterday, Warren Buffett, CEO of Berkshire Hathaway, contributed 15,971,345 "B" shares of Berkshire to five philanthropies. The shares, valued at about $2.9B, were given to the following foundations: Bill and Melinda Gates Foundation, Susan Thompson Buffett Foundation, The Sherwood Foundation, Howard G. Buffett Foundation and NoVo Foundation. Buffett's current contribution of Berkshire stock is the 15th installment of an annual giving plan he initiated in June, 2006 and increased in August, 2012. A procedural part of his plan is to annually convert sufficient "A" shares that he owns into "B" shares, which are then used to make his gifts.

ShowHide Related Items >><<
BRK.A Berkshire Hathaway
$271,420.00 /

-3210.57 (-1.17%)

BRK.A Berkshire Hathaway
$271,420.00 /

-3210.57 (-1.17%)

07/07/20 Argus
Dominion price target lowered to $80 from $87 at Argus
07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
BRK.B Berkshire Hathaway
$181.10 /

-1.68 (-0.92%)

BRK.A Berkshire Hathaway
$271,420.00 /

-3210.57 (-1.17%)

BRK.B Berkshire Hathaway
$181.10 /

-1.68 (-0.92%)

BRK.A Berkshire Hathaway
$271,420.00 /

-3210.57 (-1.17%)

BRK.B Berkshire Hathaway
$181.10 /

-1.68 (-0.92%)

BRK.A Berkshire Hathaway
$271,420.00 /

-3210.57 (-1.17%)

Tuesday
Hot Stocks
Mylan initiates voluntary recall of one lot of Daptomycin for injection » 11:38
07/07/20
07/07
11:38
07/07/20
11:38
MYL

Mylan

$16.35 /

-0.2 (-1.21%)

Mylan N.V. announced that…

Mylan N.V. announced that its U.S.-based Mylan Institutional LLC business is conducting a voluntary nationwide recall to the consumer level of one lot of Daptomycin for Injection, 500 mg/vial due to the presence of particulate matter found in one single-dose vial manufactured by Mylan Laboratories Limited's Specialty Formulation Facility. To date, Mylan has not received any reports of adverse events related to this recall. Daptomycin for injection is an injectable antibacterial indicated for the treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections in adult patients.

ShowHide Related Items >><<
MYL Mylan
$16.35 /

-0.2 (-1.21%)

MYL Mylan
$16.35 /

-0.2 (-1.21%)

06/18/20 Raymond James
Raymond James says Mylan win over Biogen has 'no real apparent financial upside'
06/18/20 Wedbush
Patent ruling 'creates a significant issue' for Biogen, says Wedbush
03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
MYL Mylan
$16.35 /

-0.2 (-1.21%)

MYL Mylan
$16.35 /

-0.2 (-1.21%)

MYL Mylan
$16.35 /

-0.2 (-1.21%)

MYL Mylan
$16.35 /

-0.2 (-1.21%)

Recommendations
Dominion price target lowered to $80 from $87 at Argus » 07:47
07/07/20
07/07
07:47
07/07/20
07:47
D

Dominion

/

+

, BRK.A

Berkshire Hathaway

$274,630.57 /

+6969.43 (+2.60%)

, BRK.B

Berkshire Hathaway

$182.78 /

+3.9 (+2.18%)

, DUK

Duke Energy

$79.79 /

-2.05 (-2.50%)

Argus analyst Jacob…

Argus analyst Jacob Kilstein lowered the firm's price target on Dominion (D) to $80 from $87 and keeps a Buy rating on the shares. The analyst is citing the impact of the company's announcement to sell its gas transmission and storage business to Berkshire Hathaway (BRK.A) for $9.7B as well as the cancellation of its Atlantic Coast Pipeline project with its partner Duke Energy (DUK) due to cost and regulatory uncertainty. Kilstein is lowering his FY20 EPS view to $3.37-$3.63 from $4.25-$4.60 while noting that Dominion shares trade at 20.4-times his expected 2020 earnings, which is above the company's 5-year range midpoint of 18.6-times.

ShowHide Related Items >><<
DUK Duke Energy
$79.79 /

-2.05 (-2.50%)

D Dominion
/

+

BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

D Dominion
/

+

07/07/20 Mizuho
Dominion downgraded to Underperform from Neutral at Mizuho
07/07/20 Credit Suisse
Dominion downgraded to Neutral from Outperform at Credit Suisse
07/06/20 Wells Fargo
Wells says merits of Dominion's 'forward-looking' deal to be clearer with time
07/06/20 Stifel
ACP cancellation negative for mainline pipeline industry overall, says Stifel
BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
BRK.B Berkshire Hathaway
$182.78 /

+3.9 (+2.18%)

DUK Duke Energy
$79.79 /

-2.05 (-2.50%)

07/06/20 JPMorgan
EQT could benefit from pipeline cancellation, says JPMorgan
06/09/20 Seaport Global
Duke Energy initiated with a Neutral at Seaport Global
DUK Duke Energy
$79.79 /

-2.05 (-2.50%)

D Dominion
/

+

BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

  • 19
    Nov
D Dominion
/

+

BRK.B Berkshire Hathaway
$182.78 /

+3.9 (+2.18%)

BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

D Dominion
/

+

BRK.B Berkshire Hathaway
$182.78 /

+3.9 (+2.18%)

BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

DUK Duke Energy
$79.79 /

-2.05 (-2.50%)

D Dominion
/

+

Monday
On The Fly
Fly Intel: Wall Street's top stories for Monday » 16:14
07/06/20
07/06
16:14
07/06/20
16:14
UBER

Uber

$32.51 /

+1.85 (+6.03%)

, BRK.A

Berkshire Hathaway

$274,630.57 /

+6969.43 (+2.60%)

, BRK.B

Berkshire Hathaway

$182.78 /

+3.9 (+2.18%)

, D

Dominion

$73.60 /

-9.085 (-10.99%)

, DUK

Duke Energy

$79.81 /

-2.03 (-2.48%)

, T

AT&T

$30.51 /

+0.43 (+1.43%)

, ET

Energy Transfer LP

$6.25 /

-0.8 (-11.36%)

, REGN

Regeneron

$626.65 /

+5.89 (+0.95%)

, MSFT

Microsoft

$210.79 /

+4.52 (+2.19%)

, EA

Electronic Arts

$134.25 /

+0.55 (+0.41%)

, TTWO

Take-Two

$145.73 /

+1.37 (+0.95%)

, ATVI

Activision Blizzard

$78.68 /

+1.25 (+1.61%)

, CRTO

Criteo

$13.23 /

+1.84 (+16.15%)

, BDX

Becton Dickinson

$250.52 /

+5.43 (+2.22%)

, OBSV

ObsEva

$3.25 /

-2.9 (-47.15%)

, BLU

Bellus Health

$3.45 /

-8.56 (-71.27%)

U.S. stock markets were…

Open Full Text

ShowHide Related Items >><<
UBER Uber
$32.51 /

+1.85 (+6.03%)

TTWO Take-Two
$145.73 /

+1.37 (+0.95%)

T AT&T
$30.51 /

+0.43 (+1.43%)

REGN Regeneron
$626.65 /

+5.89 (+0.95%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

ET Energy Transfer LP
$6.25 /

-0.8 (-11.36%)

EA Electronic Arts
$134.25 /

+0.55 (+0.41%)

DUK Duke Energy
$79.81 /

-2.03 (-2.48%)

D Dominion
$73.60 /

-9.085 (-10.99%)

CRTO Criteo
$13.23 /

+1.84 (+16.15%)

BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

BLU Bellus Health
$3.45 /

-8.56 (-71.27%)

BDX Becton Dickinson
$250.52 /

+5.43 (+2.22%)

ATVI Activision Blizzard
$78.68 /

+1.25 (+1.61%)

UBER Uber
$32.51 /

+1.85 (+6.03%)

07/07/20 KeyBanc
Uber acquisition of Postmates helps drive market rationalization, says KeyBanc
07/06/20 RBC Capital
Uber price target lowered to $45 from $52 at RBC Capital
07/06/20 Benchmark
Waitr Holdings price target raised to $5 from $4 at Benchmark
07/06/20 Wedbush
Uber's acquisition of Postmates 'a smart strategic move,' says Wedbush
BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

07/07/20 Argus
Dominion price target lowered to $80 from $87 at Argus
07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
BRK.B Berkshire Hathaway
$182.78 /

+3.9 (+2.18%)

D Dominion
$73.60 /

-9.085 (-10.99%)

07/07/20 Mizuho
Dominion downgraded to Underperform from Neutral at Mizuho
07/07/20 Credit Suisse
Dominion downgraded to Neutral from Outperform at Credit Suisse
07/06/20 Wells Fargo
Wells says merits of Dominion's 'forward-looking' deal to be clearer with time
DUK Duke Energy
$79.81 /

-2.03 (-2.48%)

07/06/20 Stifel
ACP cancellation negative for mainline pipeline industry overall, says Stifel
07/06/20 JPMorgan
EQT could benefit from pipeline cancellation, says JPMorgan
T AT&T
$30.51 /

+0.43 (+1.43%)

06/25/20 BTIG
RingCentral price target raised to $325 from $275 at BTIG
06/15/20 Stephens
Electronic Arts seems like best fit as buyer for WB Interactive, says Stephens
06/15/20 Oppenheimer
EA makes 'most sense' as potential buyer of Warner gaming unit, says Oppenheimer
06/11/20 Wells Fargo
T-Mobile price target raised to $120 from $110 at Wells Fargo
ET Energy Transfer LP
$6.25 /

-0.8 (-11.36%)

06/22/20 Citi
Energy Transfer LP price target lowered to $10 from $18 at Citi
06/09/20
Fly Intel: Top five analyst upgrades
06/09/20 BMO Capital
Energy Transfer LP upgraded to Outperform from Market Perform at BMO Capital
05/13/20 Bernstein
Energy Transfer LP price target lowered to $12 from $22 at Bernstein
REGN Regeneron
$626.65 /

+5.89 (+0.95%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

07/07/20 Loop Capital
Logitech price target raised to $78 from $58 at Loop Capital
07/06/20 Morgan Stanley
Microsoft skilling focus tempers some Pluralsight optimism, says Morgan Stanley
06/29/20 JMP Securities
ZoomInfo initiated with a Market Perform at JMP Securities
06/24/20 Bernstein
Potential spinoff would be largely positive for VMware, says Bernstein
EA Electronic Arts
$134.25 /

+0.55 (+0.41%)

07/07/20 Oppenheimer
Electronic Arts price target raised to $150 from $125 at Oppenheimer
06/26/20 Needham
Electronic Arts price target raised to $150 from $135 at Needham
06/26/20 BMO Capital
Electronic Arts price target raised to $132 from $110 at BMO Capital
06/26/20 Stephens
Electronic Arts price target raised to $145 from $130 at Stephens
TTWO Take-Two
$145.73 /

+1.37 (+0.95%)

06/12/20
Fly Intel: Top five analyst upgrades
06/12/20 MKM Partners
Take-Two upgraded to Buy after GTA V remaster announcement at MKM Partners
ATVI Activision Blizzard
$78.68 /

+1.25 (+1.61%)

07/07/20 Piper Sandler
Activision Blizzard price target raised to $86 from $79 at Piper Sandler
07/02/20 Needham
Activision Blizzard price target raised to $90 from $75 at Needham
07/01/20 BofA
BofA makes 14 additions, four deletions from US 1 list
06/29/20 Benchmark
Activision Blizzard price target raised to $85 from $77 at Benchmark
CRTO Criteo
$13.23 /

+1.84 (+16.15%)

06/24/20 BMO Capital
Criteo downgraded to Market Perform from Outperform at BMO Capital
05/08/20 Deutsche Bank
Criteo price target lowered to $16 from $22 at Deutsche Bank
05/05/20 SunTrust
Criteo price target lowered to $13 from $25 at SunTrust
04/20/20 Nomura Instinet
Criteo price target lowered to $10 from $14 at Nomura Instinet
BDX Becton Dickinson
$250.52 /

+5.43 (+2.22%)

07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
07/02/20 Wells Fargo
Becton rapid antigen COVID test may be available very soon, says Wells Fargo
06/25/20 Raymond James
Becton Dickinson price target lowered to $265 from $290 at Raymond James
06/01/20
Fly Intel: Top five analyst initiations
OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

07/07/20 Wedbush
Selloff in ObsEva shares 'overdone,' says Wedbush
07/07/20 JPMorgan
JPMorgan downgrades ObsEva, cuts target to $5 from $18
07/07/20 JPMorgan
ObsEva downgraded to Neutral from Overweight at JPMorgan
07/06/20 BMO Capital
ObsEva downgraded to Market Perform from Outperform at BMO Capital
BLU Bellus Health
$3.45 /

-8.56 (-71.27%)

07/07/20 Guggenheim
Guggenheim downgrades Bellus Health to Neutral after 'disappointing' cough trial
07/07/20 Guggenheim
Bellus Health downgraded to Neutral from Buy at Guggenheim
07/06/20 Jefferies
Jefferies cuts Bellus target to $6, sees potential for 'meaningful upside'
07/06/20 Mackie
Bellus Health downgraded to Hold from Speculative Buy at Mackie
UBER Uber
$32.51 /

+1.85 (+6.03%)

TTWO Take-Two
$145.73 /

+1.37 (+0.95%)

T AT&T
$30.51 /

+0.43 (+1.43%)

REGN Regeneron
$626.65 /

+5.89 (+0.95%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

ET Energy Transfer LP
$6.25 /

-0.8 (-11.36%)

EA Electronic Arts
$134.25 /

+0.55 (+0.41%)

DUK Duke Energy
$79.81 /

-2.03 (-2.48%)

D Dominion
$73.60 /

-9.085 (-10.99%)

CRTO Criteo
$13.23 /

+1.84 (+16.15%)

BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

BDX Becton Dickinson
$250.52 /

+5.43 (+2.22%)

ATVI Activision Blizzard
$78.68 /

+1.25 (+1.61%)

  • 27
    May
  • 21
    May
  • 11
    Feb
  • 19
    Nov
  • 07
    Nov
  • 06
    Nov
  • 05
    Sep
UBER Uber
$32.51 /

+1.85 (+6.03%)

TTWO Take-Two
$145.73 /

+1.37 (+0.95%)

T AT&T
$30.51 /

+0.43 (+1.43%)

REGN Regeneron
$626.65 /

+5.89 (+0.95%)

MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

ET Energy Transfer LP
$6.25 /

-0.8 (-11.36%)

EA Electronic Arts
$134.25 /

+0.55 (+0.41%)

D Dominion
$73.60 /

-9.085 (-10.99%)

BRK.B Berkshire Hathaway
$182.78 /

+3.9 (+2.18%)

BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

UBER Uber
$32.51 /

+1.85 (+6.03%)

T AT&T
$30.51 /

+0.43 (+1.43%)

REGN Regeneron
$626.65 /

+5.89 (+0.95%)

MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

ET Energy Transfer LP
$6.25 /

-0.8 (-11.36%)

EA Electronic Arts
$134.25 /

+0.55 (+0.41%)

D Dominion
$73.60 /

-9.085 (-10.99%)

CRTO Criteo
$13.23 /

+1.84 (+16.15%)

BRK.B Berkshire Hathaway
$182.78 /

+3.9 (+2.18%)

BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

BDX Becton Dickinson
$250.52 /

+5.43 (+2.22%)

UBER Uber
$32.51 /

+1.85 (+6.03%)

TTWO Take-Two
$145.73 /

+1.37 (+0.95%)

T AT&T
$30.51 /

+0.43 (+1.43%)

REGN Regeneron
$626.65 /

+5.89 (+0.95%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

ET Energy Transfer LP
$6.25 /

-0.8 (-11.36%)

EA Electronic Arts
$134.25 /

+0.55 (+0.41%)

DUK Duke Energy
$79.81 /

-2.03 (-2.48%)

D Dominion
$73.60 /

-9.085 (-10.99%)

ATVI Activision Blizzard
$78.68 /

+1.25 (+1.61%)

MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:02
07/06/20
07/06
12:02
07/06/20
12:02
UBER

Uber

$32.46 /

+1.8 (+5.87%)

, D

Dominion

$75.70 /

-6.98 (-8.44%)

, DUK

Duke Energy

$79.60 /

-2.24 (-2.74%)

, BRK.A

Berkshire Hathaway

$273,400.00 /

+5738.86 (+2.14%)

, REGN

Regeneron

$636.28 /

+15.52 (+2.50%)

, CRTO

Criteo

$13.53 /

+2.14 (+18.79%)

, BDX

Becton Dickinson

$252.66 /

+7.57 (+3.09%)

, BLU

Bellus Health

$2.71 /

-9.3 (-77.44%)

, OBSV

ObsEva

$3.34 /

-2.81 (-45.69%)

U.S. stock markets are…

Open Full Text

ShowHide Related Items >><<
UBER Uber
$32.46 /

+1.8 (+5.87%)

REGN Regeneron
$636.28 /

+15.52 (+2.50%)

OBSV ObsEva
$3.34 /

-2.81 (-45.69%)

DUK Duke Energy
$79.60 /

-2.24 (-2.74%)

D Dominion
$75.70 /

-6.98 (-8.44%)

CRTO Criteo
$13.53 /

+2.14 (+18.79%)

BRK.A Berkshire Hathaway
$273,400.00 /

+5738.86 (+2.14%)

BLU Bellus Health
$2.71 /

-9.3 (-77.44%)

BDX Becton Dickinson
$252.66 /

+7.57 (+3.09%)

UBER Uber
$32.46 /

+1.8 (+5.87%)

07/06/20 Benchmark
Waitr Holdings price target raised to $5 from $4 at Benchmark
07/06/20 Wedbush
Uber's acquisition of Postmates 'a smart strategic move,' says Wedbush
07/01/20 BTIG
Uber consensus likely aggressive, says BTIG
06/30/20 SunTrust
Uber shouldn't face regulatory issues if it buys Postmates, says Suntrust
D Dominion
$75.70 /

-6.98 (-8.44%)

07/06/20 JPMorgan
EQT could benefit from pipeline cancellation, says JPMorgan
07/06/20 JPMorgan
Dominion now positioned as 'best-in-class' utility, says JPMorgan
07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
06/09/20 Seaport Global
Dominion initiated with a Buy at Seaport Global
DUK Duke Energy
$79.60 /

-2.24 (-2.74%)

06/09/20 Seaport Global
Duke Energy initiated with a Neutral at Seaport Global
05/20/20 Wells Fargo
Duke Energy price target lowered to $88 from $108 at Wells Fargo
BRK.A Berkshire Hathaway
$273,400.00 /

+5738.86 (+2.14%)

04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
REGN Regeneron
$636.28 /

+15.52 (+2.50%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
CRTO Criteo
$13.53 /

+2.14 (+18.79%)

06/24/20 BMO Capital
Criteo downgraded to Market Perform from Outperform at BMO Capital
05/08/20 Deutsche Bank
Criteo price target lowered to $16 from $22 at Deutsche Bank
05/05/20 SunTrust
Criteo price target lowered to $13 from $25 at SunTrust
04/20/20 Nomura Instinet
Criteo price target lowered to $10 from $14 at Nomura Instinet
BDX Becton Dickinson
$252.66 /

+7.57 (+3.09%)

07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
07/02/20 Wells Fargo
Becton rapid antigen COVID test may be available very soon, says Wells Fargo
06/25/20 Raymond James
Becton Dickinson price target lowered to $265 from $290 at Raymond James
06/01/20
Fly Intel: Top five analyst initiations
BLU Bellus Health
$2.71 /

-9.3 (-77.44%)

07/06/20 H.C. Wainwright
H.C. Wainwright reiterates $28 target on Bellus despite Phase 2 miss
06/26/20 H.C. Wainwright
Bellus Health initiated with a Buy at H.C. Wainwright
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
09/30/19
Fly Intel: Top five analyst initiations
OBSV ObsEva
$3.34 /

-2.81 (-45.69%)

03/24/20 Wedbush
ObsEva price target lowered to $34 from $40 at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 after pipeline update at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 from $36 at Wedbush
12/19/19 H.C. Wainwright
ObsEva price target raised to $40 from $36 at H.C. Wainwright
UBER Uber
$32.46 /

+1.8 (+5.87%)

REGN Regeneron
$636.28 /

+15.52 (+2.50%)

OBSV ObsEva
$3.34 /

-2.81 (-45.69%)

DUK Duke Energy
$79.60 /

-2.24 (-2.74%)

D Dominion
$75.70 /

-6.98 (-8.44%)

CRTO Criteo
$13.53 /

+2.14 (+18.79%)

BRK.A Berkshire Hathaway
$273,400.00 /

+5738.86 (+2.14%)

BDX Becton Dickinson
$252.66 /

+7.57 (+3.09%)

  • 27
    May
  • 21
    May
  • 11
    Feb
  • 19
    Nov
  • 07
    Nov
  • 06
    Nov
  • 05
    Sep
UBER Uber
$32.46 /

+1.8 (+5.87%)

REGN Regeneron
$636.28 /

+15.52 (+2.50%)

D Dominion
$75.70 /

-6.98 (-8.44%)

BRK.A Berkshire Hathaway
$273,400.00 /

+5738.86 (+2.14%)

UBER Uber
$32.46 /

+1.8 (+5.87%)

REGN Regeneron
$636.28 /

+15.52 (+2.50%)

D Dominion
$75.70 /

-6.98 (-8.44%)

CRTO Criteo
$13.53 /

+2.14 (+18.79%)

BRK.A Berkshire Hathaway
$273,400.00 /

+5738.86 (+2.14%)

BDX Becton Dickinson
$252.66 /

+7.57 (+3.09%)

UBER Uber
$32.46 /

+1.8 (+5.87%)

REGN Regeneron
$636.28 /

+15.52 (+2.50%)

OBSV ObsEva
$3.34 /

-2.81 (-45.69%)

DUK Duke Energy
$79.60 /

-2.24 (-2.74%)

D Dominion
$75.70 /

-6.98 (-8.44%)

Conference/Events
Dominion Energy to hold a conference call » 08:55
07/06/20
07/06
08:55
07/06/20
08:55
BRK.A

Berkshire Hathaway

$267,661.14 /

+751.14 (+0.28%)

, D

Dominion

$82.68 /

+0.32 (+0.39%)

Management discusses the…

Management discusses the definitive agreement to sell substantially of Dominion Energy's Gas Transmission & Storage segment assets to an affiliate of Berkshire Hathaway on a conference call to be held on July 6 at 9 am. Webcast Link

ShowHide Related Items >><<
D Dominion
$82.68 /

+0.32 (+0.39%)

BRK.A Berkshire Hathaway
$267,661.14 /

+751.14 (+0.28%)

BRK.A Berkshire Hathaway
$267,661.14 /

+751.14 (+0.28%)

07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
D Dominion
$82.68 /

+0.32 (+0.39%)

07/06/20 JPMorgan
EQT could benefit from pipeline cancellation, says JPMorgan
07/06/20 JPMorgan
Dominion now positioned as 'best-in-class' utility, says JPMorgan
06/09/20 Seaport Global
Dominion initiated with a Buy at Seaport Global
D Dominion
$82.68 /

+0.32 (+0.39%)

BRK.A Berkshire Hathaway
$267,661.14 /

+751.14 (+0.28%)

D Dominion
$82.68 /

+0.32 (+0.39%)

BRK.A Berkshire Hathaway
$267,661.14 /

+751.14 (+0.28%)

D Dominion
$82.68 /

+0.32 (+0.39%)

BRK.A Berkshire Hathaway
$267,661.14 /

+751.14 (+0.28%)

D Dominion
$82.68 /

+0.32 (+0.39%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.